Preventing Adverse Drug Events With PatientSite
2 other identifiers
interventional
800
1 country
1
Brief Summary
This is a study to better understand the nature and extent of adverse drug events (ADEs), defined as injuries due to prescription medications, in primary care. We will study whether PatientSite (an internet-based communication program for patients and health care providers) can improve clinicians' ability to detect adverse drug events among primary care patients and to mitigate the consequences by sending electronic queries to patients after they receive new medication prescriptions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Apr 2003
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2003
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2004
CompletedFirst Submitted
Initial submission to the registry
August 30, 2005
CompletedFirst Posted
Study publicly available on registry
September 1, 2005
CompletedFebruary 26, 2013
February 1, 2013
1.7 years
August 30, 2005
February 24, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To prevent adverse drug events with PatientSite.
3 years
Secondary Outcomes (3)
Improve patient satisfaction
3 years
better utilization of services
3 years
improve patient-clinician communication
3 years
Study Arms (2)
MedCheck
EXPERIMENTALElectronic medication safety queries via PatientSite portal
Usual care
NO INTERVENTIONNo electronic medication safety messages via PatientSite portal
Interventions
Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician
Eligibility Criteria
You may qualify if:
- Adult patients \>18
- Patients that receive a new prescription
- Proficient in spoken and written english
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dana-Farber Cancer Institutelead
- Agency for Healthcare Research and Quality (AHRQ)collaborator
- Blue Cross Blue Shieldcollaborator
- Beth Israel Deaconess Medical Centercollaborator
Study Sites (1)
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Related Publications (1)
Weingart SN, Carbo A, Tess A, Chiappetta L, Tutkus S, Morway L, Toth M, Davis RB, Phillips RS, Bates DW. Using a patient internet portal to prevent adverse drug events: a randomized, controlled trial. J Patient Saf. 2013 Sep;9(3):169-75. doi: 10.1097/PTS.0b013e31829e4b95.
PMID: 23965840DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Saul N Weingart, MD, PhD
Dana-Farber Cancer Institute
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- VP for Quality Improvement and Patient Safety
Study Record Dates
First Submitted
August 30, 2005
First Posted
September 1, 2005
Study Start
April 1, 2003
Primary Completion
December 1, 2004
Study Completion
December 1, 2004
Last Updated
February 26, 2013
Record last verified: 2013-02